Skip to main content
SpringerLink
Log in

Pharmacological Profile of Antihypertensive Drugs with Serotonin Receptor and α-Adrenoceptor Activity

Drugs volume 40, pages 1–8 (1990)Cite this article

Summary

During the last few years, several antihypertensive drugs with multiple actions have been introduced. Most of these hybrid drugs are β-adrenoceptor blockers with an additional vasodilator component, such as labetalol, dilevalol, carvedilol and celiprolol.

A second category of antihypertensive drugs with multiple actions consists of agents which interact simultaneously with serotoninergic receptors and gα-adrenoceptors. Urapidil, ketanserin, and a few experimental compounds related to these drugs are examples of this type of antihypertensive. They may be characterised pharmacologically as follows: (1) Ketanserin is a selective antagonist of serotonin2 receptors with an additional much weaker α1-adrenoceptor antagonistic activity. Its well documented antihypertensive activity cannot be explained by either serotonin2-receptor blockade or α-adrenoceptor antagonism alone. An unknown type of interaction between serotonin-receptor and α1-adrenoceptor blockade appears to be necessary, either in the periphery or in the CNS. (2) Urapidil is a selective α1-adrenoceptor antagonist and, as such, a peripheral vasodilator. In addition, it displays central hypotensive activity, probably caused by the stimulation of serotonin1A receptors in the CNS. This component is probably additive to the peripheral effect, and is also the background to the lack of reflex tachycardia seen with urapidil.

The modes of action of both types of drugs are discussed in connection with the role of serotonin and its receptors in the cardiovascular system, both at the peripheral and the CNS levels.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  • Blauw GJ, Van Brummelen P, Chang PC, Van Zwieten PA. Regional vascular effects of serotonin and ketanserin in young healthy subjects. Hypertension 11: 256–263, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Blauw GJ, Van Brummelen P, Chang PC, Vermeij P, Van Zwieten PA. Arterial dilatation and venous constriction induced by serotonin in the elderly. Drugs 36 (Suppl. 1): 74–77, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Blauw GJ, Van Brummelen P, Doorenbos CJ, Van Zwieten PA. No evident vascular 5HT2 -and α1-adrenoceptor blockade during anti-hypertensive treatment with ketanserin. 13th Scientific Meeting of the International Society of Hypertension, Montréal, June, 1990

  • Breckenridge A. Ageing, serotonin and ketanserin. Drugs 36 (Suppl. 1): 44–55, 1988

    Article  PubMed  Google Scholar 

  • Buehler F, Amstein R, Fetkovska N. Age and platelet serotonin in essential hypertension. Progress in Pharmacology 7: 77–83, 1990

    Google Scholar 

  • Buehler F, Amann FW, Bolli P. Elevated adrenaline and increased α-adrenoceptor-mediated vasoconstriction in essential hypertension. Journal of Cardiovascular Pharmacology 4 (Suppl. 1): S134–S138, 1982

    Article  Google Scholar 

  • Cohen ML, Kurz KD, Maton MR, Fulder KW, Marzoni GP, et al. Pharmacological activity of the isomers of LY 53587, a potent and selective 5HT2-receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 235: 319–325, 1985

    PubMed  CAS  Google Scholar 

  • Copeland IW, Bentley GA. A possible central action of prazosin and ketanserin to cause hypertension. Journal of Cardiovascular Pharmacology 7: 822–825, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dabire H, Cherqui C, Fournier B, Schmitt H. Comparison of effects of some 5HT1A-agonists on blood pressure and heart rate of normotensive anaesthetized rats. European Journal of Pharmacology 140: 259–266, 1987

    Article  PubMed  CAS  Google Scholar 

  • Doods HN, Boddeke HWGM, Kalkman HO, Hoyer D, Mathy M-J, et al. Central 5HT1A-receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R 28935 and urapidil. Journal of Cardiovascular Pharmacology 11: 432–437, 1988

    Article  PubMed  CAS  Google Scholar 

  • Dragstedt N, Boeck V. Cardiovascular effects of irindalone, a novel 5HT2-receptor antagonist with antihypertensive activity. International Symposium on Serotonin, Florence, March 1989. Abstract book, p. 138

  • Fetkovska N, Pletscher A, Ferracin F, Amstein R, Buehler F. Impaired platelet uptake of 5-hydroxytryptamine in essential hypertension: clinical relevance. Cardiovascular Drugs and Therapy 4: 105–109, 1990

    Article  PubMed  Google Scholar 

  • Finch L. Vascular reactivity in hypertensive rats after treatment with antihypertensive agents. Life Sciences 15: 1827–1837, 1974

    Article  PubMed  CAS  Google Scholar 

  • Fozard JR, Mir AK. Are 5HT-receptors involved in the antihypertensive effects of urapidil. British Journal of Pharmacology 90: 24P, 1987

    Google Scholar 

  • Fozard JR, Mir AK, Middlemiss DN. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. Journal of Cardiovascular Pharmacology 9: 328–347, 1987

    Article  PubMed  CAS  Google Scholar 

  • Frohlich E. Irvine H. Page lecture: the mosaic of hypertension: past, present and future. Journal of Hypertension 6 (Suppl. 4): S2–S11, 1988

    PubMed  CAS  Google Scholar 

  • Gillis RA, Kellar KJ, Quest JA, Namath IJ, Martino-Barrows A, et al. Experimental studies on the neurocardiovascular effects of urapidil. Drugs 35 (Suppl. 6): 20–33, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gross G, Hanft G, Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5HT) binding sites of the 5HT1A-subtype and for α1-adrenoceptor binding sites. Naunyn-Schmiedeberg’s Archives of Pharmacology 336: 597–601, 1987

    Article  PubMed  CAS  Google Scholar 

  • Head GA, Korner PI, Lewis SL, Badoer E. Contribution of noradrenergic and serotonergic neurons to the circulatory effects of centrally acting clonidine and α-methyldopa in rabbits. Journal of Cardiovascular Pharmacology 5: 945–953, 1983

    Article  PubMed  CAS  Google Scholar 

  • Howe PRC, Kuhn DM, Minson JB, Stead BH, Chalmers JP. Evidence for a bulbospinal serotonergic pressor pathway in the rat brain. Brain Research 270: 29–34, 1983

    Article  PubMed  CAS  Google Scholar 

  • Huchet AM, Doursont MF, Chelly J, Schmitt H. Possible role of central α-adrenoceptors in the control of the autonomic nervous system in normotensive and spontaneously hypertensive rats. European Journal of Pharmacology 85: 239–242, 1982

    Article  PubMed  CAS  Google Scholar 

  • Jie K, Van Brummelen P, Vermeij P, Timmermans PBMWM, Van Zwieten PA. α1 -and α2-Adrenoceptor-mediated vasoconstriction in the forearm of normotensive and hypertensive subjects. Journal of Cardiovascular Pharmacology 8: 190–196, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kolassa N, Beller KD, Sanders KH. Involvement of brain 5HT1A-receptors in the hypotensive response to urapidil. American Journal of Cardiology 64: 7D–10D, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kuhn DM, Wolf WA, Lovenberg W. Review of the role of central serotonergic neuronal systems in blood pressure regulation. Hypertension 2: 243–255, 1980

    Article  PubMed  CAS  Google Scholar 

  • Langtry HD, Mammen GJ, Sorkin EM. Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 38: 900–940, 1989

    CAS  Google Scholar 

  • McCall RB, Patel BN, Harris LT. Effects of serotonin, receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. Journal of Pharmacology and Experimental Therapeutics 242: 1152–1159, 1987

    PubMed  CAS  Google Scholar 

  • Minson J, Chalmers J, Drolet G, Kapoor V, Llewellyn-Smith I, et-al. Central serotonergic mechanisms in cardiovascular regulation. Cardiovascular Drugs and Therapy 4: 27–32, 1990

    Article  PubMed  Google Scholar 

  • Prevention of Atherosclerotic Complications with Ketanserin (PACK) Trial Group. Prevention of atherosclerotic complications: controlled trial of ketanserin. Lancet 1: 424–430, 1989

    Google Scholar 

  • Prichard BNC, Tomlinson B, Renondin JC. Urapidil, a multiple action alpha-blocking drug. American Journal of Cardiology 64: 11D-15D, 1989

    Article  Google Scholar 

  • Robertson JIS, Stott DJ, Ball SG. The serotonin antagonist ketanserin in the treatment of clinical hypertension: a short review. Journal of Hypertension 4 (Suppl. 5): S119–S121, 1986

    Article  Google Scholar 

  • Sanders KH, Beller KD, Eltze M, Kolassa N. Urapidil and some analogs with high affinities for serotonin-1a and α1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Current Opinion in Cardiology 4 (Suppl. 4): S49–S55, 1989

    Google Scholar 

  • Schoetensack W, Bruckschen EG, Zech K. Urapidil. In Scriabine A (Ed.) New drugs annual: cardiovascular drugs, pp. 19–48, Raven Press, New York, 1983

    Google Scholar 

  • Vanhoutte PM (Ed.) Serotonin and the cardiovascular system, pp. 1–169, Raven Press, New York, 1985

    Google Scholar 

  • Vanhoutte PM, Ball SG, Berdeaux A, Cohen ML, Hedner T, et al. Mechanism of action of ketanserin in hypertension. Trends in Pharmacological Sciences 7: 58–59, 1986

    Article  CAS  Google Scholar 

  • vanNueten J. Interactions between 5HT2-receptors and α1-adrenoceptors in vascular tissues. Progess in Pharmacology, in press

  • van Nueten JM, Janssen PAJ, Symoens J, Janssens WJ, Heykants J, et al. In Scriabine A (Ed.) New cardiovascular drugs, pp. 1–56, Raven Press, New York, 1987

  • van Zwieten PA, De Jonge A, Wilffert B, Timmermans PBMWM, Beckeringh JJ, et al. Cardiovascular effects and interaction with adrenoceptors of urapidil. Archives Internationales de Pharmacodynamie et de Thérapie 276: 180–201, 1985a

    PubMed  Google Scholar 

  • vanZwieten PA, Mathy M-J, Boddeke HWGM, Doods HN. Central hypotensive activity of ketanserin in cats. Journal of Cardiovascular Pharmacology 10 (Suppl. 3): S54–S58, 1987

    PubMed  Google Scholar 

  • van Zwieten PA, Mathy M-J, Thoolen MJMC. Deviating central hypotensive activity of urapidil in the cat. Journal of Pharmacy and Pharmacology 37: 810–811, 1985b

    Article  PubMed  Google Scholar 

  • van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 6 (Suppl. 11): 28–33, 1984

    Google Scholar 

  • Webb RC. Increased vascular sensitivity to serotonin and methysergide in hypertension in rats. Clinical Science 63: 73S–77S, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacotherapy and Cardiology, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105, AZ Amsterdam, The Netherlands

    P. A. van Zwieten & G. J. Blauw

  2. Department of Nephrology, Academic Hospital, University of Leiden, Leiden, The Netherlands

    G. J. Blauw

  3. Department of Medicine, Hoffmann-La Roche AG, Basle, Switzerland

    P. van Brummelen

Authors
  1. P. A. van Zwieten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. J. Blauw
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. van Brummelen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van Zwieten, P.A., Blauw, G.J. & van Brummelen, P. Pharmacological Profile of Antihypertensive Drugs with Serotonin Receptor and α-Adrenoceptor Activity. Drugs 40 (Suppl 4), 1–8 (1990). https://doi.org/10.2165/00003495-199000404-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199000404-00003

Keywords

search

Navigation